Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

Edwards Lifesciences' (EW) robust potential in the TAVR (Transcatheter Aortic Valve Replacement) business is poised to help it grow in the upcoming quarters. The company's decision to sell the Critical Care arm supports its goal of developing a comprehensive structural heart portfolio. Also, sound solvency instills optimism. However, rising costs and adverse currency impacts remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has dropped 11.3% against the 9.3% rise of the indu ...